Regeneron Pharmaceuticals Inc

REGN

Equity

ISIN US75886F1075 / Valor 965755

NASDAQ (2025-04-03)

USD 610.64-2.39%

Regeneron Pharmaceuticals Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Regeneron Pharmaceuticals Inc. is a prominent biotechnology firm that specializes in the discovery, development, and commercialization of innovative medicines aimed at transforming the lives of patients suffering from serious diseases. Since its inception over three decades ago by a team of physician-scientists, the company has established a reputation for its consistent ability to convert scientific discoveries into a range of FDA-approved treatments, with a significant portion of its product portfolio being developed in-house. Regeneron focuses on addressing a variety of medical conditions, including eye diseases, allergic and inflammatory disorders, cancer, cardiovascular and metabolic issues, pain, hematologic conditions, infectious diseases, and rare diseases. The company is also known for its pioneering VelociSuite® technologies, notably VelocImmune®, which leverages genetically-engineered mice to produce fully-human antibodies, and its involvement in one of the world's most ambitious genetics sequencing projects through the Regeneron Genetics Center®. These efforts underscore Regeneron's commitment to enhancing and expediting the drug development process, positioning it as a leader in the biotechnology sector.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

In the fourth quarter of 2024, Regeneron Pharmaceuticals Inc. reported a 10% increase in revenues, reaching $3.79 billion compared to the same quarter in 2023. For the full year 2024, revenues rose by 8% to $14.20 billion, excluding Ronapreve, which marked a 10% increase from the previous year.

Product Sales

Regeneron Pharmaceuticals Inc. saw a significant rise in product sales during the fourth quarter of 2024. Dupixent's global net sales, recorded by Sanofi, increased by 15% to $3.70 billion, while Libtayo's global net sales surged by 50% to $367 million compared to the fourth quarter of 2023.

Earnings Per Share

For the fourth quarter of 2024, Regeneron Pharmaceuticals Inc. reported a GAAP diluted earnings per share (EPS) of $8.06 and a non-GAAP diluted EPS of $12.07. The results included an unfavorable $0.11 impact from an acquired in-process research and development charge.

Dividend and Share Repurchase

Regeneron Pharmaceuticals Inc. initiated a quarterly cash dividend program, declaring a dividend of $0.88 per share. Additionally, the company authorized an additional $3.0 billion share repurchase program, increasing the total repurchase capacity to approximately $4.5 billion.

Financial Outlook

Regeneron Pharmaceuticals Inc. emphasized its strong financial and commercial position, which supports continued investment in its research and development pipeline. The company plans to focus on its four blockbuster medicines and progress its approximately 40 investigational candidates with expansive market potential in 2025.

Summarized from source with an LLMView Source

Key figures

-35.8%1Y

-12.1%3Y

23.8%5Y

Performance

24.4%1Y

27.2%3Y

30.2%5Y

Volatility